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We evaluated the frequency of fatigue in geriatric patients with and without Parkinson’s disease (PD) and correlated it with
depression and excessive daytime sleepiness. We evaluated 100 patients from Hospital São Paulo, 50 with PD from the
Neurologic Outpatient Clinic and 50 with non-neurologic diseases or oncologic diseases from the Geriatric Outpatient Clinic
(controls). All patients who scored 28 or more on the Fatigue Severity Scale (FSS) were considered to have fatigue. Also, all
patients were submitted to a structured interview to diagnose depression by the criteria of the American Psychiatric Association
(DSM-IV, 4th version) and were evaluated by the Modified Impact of Fatigue Scale and the Epworth Sleepiness Scale (ESE) to
detect excessive daytime sleepiness. Demographic and disease details of all PD patients were recorded and the patients were
examined and rated by the Unified Parkinson’s Disease Rating Sale (UPDRS) and Hoehn-Yahr staging. Frequency of fatigue
(FSS ≥28) was 70% for PD and 22% for controls. Twenty of 35 PD patients with fatigue had concomitant depression. Compared
to controls, PD patients were found more frequently to have depression by DSM-IV criteria (44 vs 8%, respectively) and
excessive daytime sleepiness by the ESE (44 vs 16%), although only depression was associated with fatigue. Fatigue was more
frequent among depressed PD and control patients and was not correlated with PD duration or with UPDRS motor scores. ESE
scores did not differ between patients with or without fatigue.
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Introduction
Fatigue is a most prevalent symptom in many clinical
conditions, particularly Parkinson’s disease (PD). The main
signs and symptoms of PD are rest tremor, muscular
rigidity, akinesia and postural and balance disorders, all of
them of a motor nature. Non-motor symptoms are also
quite common in PD but have been neglected. Fatigue is
one of the more frequent non-motor manifestations of PD
and can affect 40 to 56% of the patients (1-3).
In clinical conditions where fatigue is present there is a
frequent association with depression and excessive day-
time sleepiness. Both depression and excessive daytime
sleepiness are also frequent in PD and may coexist with
fatigue but it has not been established if they have a cause
and effect relationship.
A study of 313 depressed chronic patients treated and
followed-up over a period of 10 years showed that fatigue
was the most powerful indicator of worsening of disease
symptoms (4). Even in successfully treated patients, fa-
tigue may persist in 10 to 35% of major depression cases
(5,6).
Sleep disorders are also common in PD and may be
present in 74 to 98% of the patients (7-9). Sleep disorders
seem to be caused by neurotransmitter abnormalities other
than degeneration of the dopaminergic pathway and may
be associated with the use of dopaminergic agents (7). The
most frequent sleep disorders in PD include insomnia,
772
Braz J Med Biol Res 42(8) 2009
F.O. Goulart et al.
www.bjournal.com.br
excessive daytime sleepiness, restless legs syndrome,
REM sleep behavior disorders, and sleep apnea (10).
Excessive daytime sleepiness may affect 15 to 65% of PD
patients (11-14).
Since fatigue is prevalent in PD and in other clinical
conditions of the elderly, one could raise the question if
fatigue in PD is a specific symptom of the disease or merely
a symptom associated with patient age. The aim of the
present study was to detect the presence of fatigue in a
cohort of geriatric patients older than 60 years with and
without PD. Secondarily, we explored the relationship of
fatigue with excessive daytime sleepiness and depression.
Patients and Methods
We evaluated 50 PD patients who comprised the
Parkinson Group and 50 geriatric patients without PD who
comprised the control group. All 100 patients were se-
lected from the outpatient clinic of Hospital São Paulo,
Universidade Federal de São Paulo (UNIFESP). PD pa-
tients were followed-up at the Movement Disorders Unit of
the Department of Neurology and controls were followed-
up at the Geriatric outpatient clinic of the Department of
Medicine.
PD patients had to be older than 60 years and were
diagnosed according to the United Kingdom Parkinson’s
Disease Society Brain Bank Clinical Criteria (15).
Control patients were geriatric patients followed due to
chronic clinical diseases such as arterial hypertension,
cardiac failure, chronic respiratory diseases, digestive dis-
orders, etc. We excluded from both groups patients younger
than 60 years, those who had received any drug with
antidopaminergic effects during the past 24 weeks, and
also those who had any oncologic, rheumatologic or neu-
rologic disease other than PD.
Demographic data were recorded for all patients, such
as gender, age, medication in use and disease duration.
All patients were submitted to a structured interview with
the neurologists involved in this study, answering ques-
tions of the items of the American Psychiatric Association
(DSM-IV, 4th version) criteria for depression (16). All PD
patients were evaluated by the Hoehn-Yahr staging scale
(17) and by the Unified Parkinson’s Disease Rating Scale
part 3 (UPDRS motor score) to measure motor impairment
(18).
All 100 patients were evaluated by the Beck Depres-
sion Inventory (BDI) (19), Mini-Mental State Examination
(20) and fatigue scales. The Epworth Sleepiness Scale
was applied to all patients and those who scored more than
10 were considered to have excessive daytime sleepiness
(21). We used the Fatigue Severity Scale (FSS) (22) and
Modified Fatigue Impact Scale (MFIS) to rate fatigue in our
patients (23).
Both fatigue scales used had been previously vali-
dated for the Portuguese language (24). We considered
fatigue to be present if patients scored 28 or more on the
FSS (24).
Data were analyzed statistically by the Student t-test to
compare two independent samples, by the chi-square or
Fisher exact test, where applicable, to analyze correlation
between two independent samples, and by Pearson and
Spearman coefficients to quantify the linear relation and
the tendency of growing between two quantitative vari-
ables, respectively.
Data were analyzed using the Statistical Package for
the Social Sciences (SPSS) software, version 11.0 for
Windows.
The study was approved by the Ethics Committee of
Hospital São Paulo (process #0156-06) and written in-
formed consent was obtained from each patient.
Results and Discussion
The demographic characteristics of both groups are
shown in Table 1. Women predominated in controls and
the mean ages of the patients were similar in both groups.
Fatigue and depression were more frequent in PD patients
than in controls. PD patients had higher scores on the
Epworth Sleepiness Scale.
There was no correlation between duration of PD symp-
toms and FSS scores. Mean UPDRS motor scores were
similar for PD patients with and without fatigue.
Table 2 shows that fatigue was significantly correlated
with depression as diagnosed by DSM-IV criteria in both
the PD group and the control group.
The mean scores of the Epworth Sleepiness Scale for
patients with and without fatigue in both groups (PD and
controls) were not significantly different.
The control group had a high prevalence of women.
One could argue that this could be a source of bias be-
cause depression is usually more prevalent in women.
However, we observed only an 8% frequency of depres-
sion in our control patients as opposed to 44% in PD
patients.
The present study showed that 70% of PD patients had
fatigue, a higher frequency than usually reported in other
surveys. The prevalence of fatigue among PD patients has
been reported to range from 32 to 56% (2,3,25). PD pa-
tients in the early phase of symptoms may have a 30%
prevalence of fatigue and this rate can rise to 50% if they
are followed-up for a period of 42 weeks (26). Our PD
patients had an average duration of symptoms of 6.3 years
773
Braz J Med Biol Res 42(8) 2009
Fatigue in geriatric and Parkinson’s disease patients
www.bjournal.com.br
and this longer duration of the disease may explain the
higher frequency of fatigue among them. On the other
hand, there was no correlation between FSS scores and
duration of symptoms. In other words, the duration of PD
may be important for the development of fatigue but not for
its severity.
Fatigue was observed in 22% of our control geriatric
patients, which could be considered to be a high proportion
of patients in comparison with the general population.
However, elderly subjects have a relatively high preva-
lence of fatigue, especially those with clinical problems, as
was the case for our control sample (27,28).
Depression was detected in 44% of PD patients and
8% of control patients, as shown in Table 1. Depression
can affect 40 to 50% of PD patients and less than 10% of
elderly people (29). Our PD patients with depression had
higher BDI scores than the geriatric patients without PD,
suggesting that depression, when present, is more severe
among PD patients. However, we could also explain these
findings by the small number of depressed individuals in
the control group or by the choice of BDI to measure the
severity of depression. BDI has many questions regarding
somatic symptoms and some of them could be confounded
with some non-motor symptoms of PD. PD patients have
depression more frequently than patients with other chronic
neurological diseases. Depression can be the first mani-
festation of PD and may cause functional disability by itself
in patients with mild motor symptoms (30,31).
Schifitto et al. (26) demonstrated that fatigue and se-
verity of motor symptoms could be correlated. However,
our study did not demonstrate a correlation between fa-
tigue and duration or severity of PD, and the same was
also reported by others (1,2,23,32). Non-motor manifesta-
tions of PD, such as olfaction disorder, constipation and
depression may precede motor symptoms by many years
(33). Fatigue is one of these non-motor symptoms and is
Table 1. Characteristics of the Parkinson’s disease and control groups.
Parkinson’s disease Control Total
Women/Men 28/22* 43/7 71/29
Age (mean in years) 70.5 73.9 72.2
Hoehn-Yahr Stage (mean) 2.53 - -
UPDRS motor score (mean score) 31.5 - -
Duration of Parkinson’s disease (mean in years) 6.3 - -
Mini-Mental State Examination (mean score) 25.8 26.0 25.9
Beck Depression Inventory (mean score) 14.1* 5.6 9.8
Fatigue Severity Scale (mean score) 37.1* 20.4 28.7
Total MFIS (mean score) 36.1* 15.4 25.7
Epworth Sleepiness Scale (mean score) 9.3* 5.7 7.5
Presence of fatigue according to FSS (FSS ≥28) 35 (70%)* 11 (22%) 46 (46%)
Presence of depression according to DSM-IV 22 (44%)* 4 (8%) 26 (26%)
With excessive daytime sleepiness (ESE ≥10) 22 (44%)* 8 (16%) 30 (30%)
UPDRS = Unified Parkinson’s Disease Rating Scale; FSS = Fatigue Severity Scale; MFIS = Modified Fatigue
Impact Scale; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders; ESE = Epworth Sleepiness
Scale. *P < 0.05 compared to control group (chi-square test and Student t-test).
Table 2. Fatigue (FSS ≥28) and depression (DSM-IV) in the Parkinson’s disease and control groups.
Without depression With depression
Parkinson’s disease Control Parkinson’s disease Control
Without fatigue 13 (26%) 38 (76%) 2 (4%) 1 (2%)
With fatigue 15 (30%) 8 (16%) 20 (40%) 3 (6%)
Total 28 (56%) 46 (92%) 22 (44%) 4 (8%)
Data are reported as number and percent. FSS = Fatigue Severity Scale; DSM-IV = Diagnostic and Statistical
Manual of Mental Disorders. Fatigue was associated with depression in both the Parkinson’s disease and
control groups (P < 0.05, chi-square test).
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probably not related to dopaminergic dysfunction. This
could explain why we did not correlate it with higher motor
scores on the UPDRS.
Table 2 shows that depression was associated with
fatigue in both the PD and control groups. A survey con-
ducted in Norway using the same methodology as in the
present study found that fatigue was present in 44% of PD
patients and in 18% of control subjects (2) and that fatigue
was associated with depression, as also observed here.
Although fatigue and depression may be associated, treat-
ing depression does not improve fatigue (32). A Japanese
study did not detect an association between fatigue and
depression (34).
Excessive daytime sleepiness was found in 44% of PD
patients and in 16% of control patients. Dopaminergic
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